1,3,5-triazine derivative and method of using same
US10654826B2 · kind B2 · utility
0Cited by
1References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 29, 2016 |
| Grant date | May 19, 2020 |
| Priority date | — |
| Expiry date | Jul 29, 2036 |
Classification
- Technology area (CPC —)General
Abstract
Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.